Precision care, at no cost to the patient. That’s what makes us ethical.
Imagine starting treatment for HER2+ cancer knowing the drug you’re taking is likely to work for your genetics.
Not guessing. Not hoping. Knowing.
At EthicaMeds, we make that possible.
We test every HER2+ cancer patient at our cost — using advanced science to see which drugs are most likely to work based on their unique genetic profile. And when our biosimilar is the right fit, we supply the medicine, too.
No wasted time.
No unnecessary side effects.
No false hope.
Just answers — and a path forward.
This isn’t a dream.
This is how we treat cancer now!
We're not ethical because we’re anti-profit.
We’re ethical because we put human life and health outcomes first — and we know the future belongs to companies that do the same.
We believe that in 10–20 years, this principle — combined with our unmatched speed in biosimilar and companion diagnostic development — will make us the most trusted pharmaceutical company on the planet.
And we’re starting right now with HER2+ cancers.
We cover the testing cost — because no one should pay just to find out a drug won’t work.
We supply the medicine — when our biosimilar is a match, we provide it directly to your provider or care team.
We do the testing — using our advanced GigaAssay™ to analyze all 5,886 HER2+ mutations (not just the common ones).
We’re not just a lab.
We’re not just a drug company.
We’re the first to do both — ethically.
We test every HER2+ cancer patient at our cost — then deliver the medicine that’s most likely to work for their genetics.
Before you take any drug, wouldn’t you want to know if it has a real chance of helping?
With EthicaMeds, you can.
We offer the first test of its kind — one that reveals if your specific genetics will allow a HER2+ drug to work. And if it won’t, we don’t stop there — we help you get the one that might.
Most HER2+ cancer patients receive treatments based on guesswork — often with drugs that will never work due to specific, untested mutations.
We're changing that.
We offer the world’s first comprehensive genetic test for HER2+ cancers. Not just testing for the 10 most common mutations. We test for all 5,886 mutations in the tyrosine kinase (TK) region — and analyze what each mutation means when exposed to HER2-targeting drugs.
We also identified 112 new mutations that are strongly associated with breast cancer — and tested every major HER2 drug, including our biosimilar, against each of them.
GigaAssay™: High-throughput testing of millions of genetic variants for drug response.
Genomic Multiplex Library (GML): Enables large-scale, real-time genetic analysis.
Outcome: The right medicine for the right patient, backed by real-world functional data.
We’re not just another drug company.
We’re the first ethical drug company — and the only one proving treatment value before the first prescription is written.
Where testing comes before guessing.
And where science serves humanity — not just shareholders.
